Who are Dapagliflozin (DAPA)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dapagliflozin / metFORMIN Pill, Maintenance treatment, Empagliflozin (EMPA), Weight Based Group, Insulin/Dapaglifozin, Empa.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapagliflozin-dapa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dapagliflozin (DAPA) — Competitive Intelligence Brief

Dapagliflozin (DAPA) (Dapagliflozin (DAPA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes, Cardiovascular.

marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2) Diabetes, Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dapagliflozin (DAPA) (Dapagliflozin (DAPA)) — Ottawa Heart Institute Research Corporation. Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dapagliflozin (DAPA) TARGET	Dapagliflozin (DAPA)	Ottawa Heart Institute Research Corporation	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Dapagliflozin / metFORMIN Pill	Dapagliflozin / metFORMIN Pill	Tan Tock Seng Hospital	marketed	SGLT2 inhibitor / Biguanide combination	SGLT2 (sodium-glucose cotransporter 2) / AMPK (AMP-activated protein kinase)
Maintenance treatment	Maintenance treatment	RWTH Aachen University	marketed	SGLT2 inhibitor	SGLT2
Empagliflozin (EMPA)	Empagliflozin (EMPA)	University of Sao Paulo	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Weight Based Group	Weight Based Group	University of Colorado, Denver	marketed	SGLT2 inhibitor	SGLT2
Insulin/Dapaglifozin	Insulin/Dapaglifozin	University of Campania Luigi Vanvitelli	marketed	Insulin + SGLT2 inhibitor combination	Insulin receptor; SGLT2 (sodium-glucose cotransporter 2)
Empa	Empa	Beni-Suef University	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dapagliflozin (DAPA) — Competitive Intelligence Brief. https://druglandscape.com/ci/dapagliflozin-dapa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab